BridgeMD
New treatment option for Dental Caries
Official title Clinical and Radiographic Assessment of Photobiomodulated MTA Pulpotomy in Immature First Permanent Molars with Irreversible Pulpitis
ClinicalTrials.gov ID: NCT06730360
What this study is testing
- What it's testing
- This study evaluates the effectiveness of photobiomodulation (PBM) in conjunction with mineral trioxide aggregate (MTA) pulpotomy for treating irreversible pulpitis in immature first permanent molars. PBM, also known as low-level laser therapy (LLLT), is used to enhance healing, reduce inflammation, and manage pain in young teeth.
- Time commitment: about 15 months
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 6 to 9
You may be able to join if
- Children aged 6 to 9 years.
- Non-contributory medical history (healthy otherwise).
- Presence of carious first permanent molars with the following characteristics:
- Deep caries extending to ≥2/3 of dentin.
- Positive response to cold testing.
You likely can't join if
- Insufficient bleeding after pulp exposure (indicating necrotic or partially necrotic pulp).
- Presence of systemic or medical conditions that may contraindicate participation.
- Teeth with unrestorable structure.
- Teeth showing signs of pulpal necrosis, such as the presence of a sinus tract or swelling.
See the full eligibility criteria
- Children aged 6 to 9 years.
- Non-contributory medical history (healthy otherwise).
- Presence of carious first permanent molars with the following characteristics:
- Deep caries extending to ≥2/3 of dentin.
- Positive response to cold testing.
- Clinical diagnosis of irreversible pulpitis (moderate or severe), with or without periapical periodontitis.
- Restorable tooth.
- Probing pocket depth and mobility within normal limits.
- No signs of pulpal necrosis, including sinus tract or swelling.
- Insufficient bleeding after pulp exposure (indicating necrotic or partially necrotic pulp).
- Presence of systemic or medical conditions that may contraindicate participation.
- Teeth with unrestorable structure.
- Teeth showing signs of pulpal necrosis, such as the presence of a sinus tract or swelling.
The study team makes the final eligibility decision.
Where it's taking place
- Al Mansurah, Dakahlia Governorate, Egypt
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 15 months per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 6 years to 9 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Al Mansurah, Dakahlia Governorate, Egypt. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.